SPRY

ARS Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-09

Figures on this page computed 2026-11-08 12:40 UTC

Last close

3.05USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-09

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-09
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-13
The filing itself
-203.3%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
-203.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-K for 2025, filed 2026-03-09
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
- 10-K for 2025, filed 2026-03-09
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.02 against 0.46 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.34x

3.95x

3.98x

3.89x

0.25x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-09

Sales2.34x
Its own average over 5 years, 36.1M.
Profit3.95x
Its own average over 8 years, -43.4M.
Free cash flow3.98x
Its own average over 8 years, -43.0M.
Debt3.89x
Its own average over 5 years, 24.8M.
Price0.25x
Its own average over 7 years, 12. Market data, 2026-11-04

Free cash flow is furthest from its own average, at 3.98 times.

Sales is 2.34 times its own 5-year average; Profit is 3.95 times its own 8-year average; Free cash flow is 3.98 times its own 8-year average; Debt is 3.89 times its own 5-year average; Price is 0.25 times its own 7-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-09

Sales against its own 5-year average2.34
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
The filing itself
Profit against its own 8-year average3.95
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
The filing itself
Free cash flow against its own 8-year average3.98
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
The filing itself
Debt against its own 5-year average3.89
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-097478
Reported in
USD
The filing itself
Price against its own 7-year average0.25Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD